City of Hope receives $32.3 million from the California Institute for Regenerative Medicine to advance innovative therapies for patients
Retrieved on:
Wednesday, August 9, 2023
City of Hope, Diabetes, Bone marrow, California Institute for Regenerative Medicine, University of California, San Diego Performance-Based Skills Assessment, Patient, Division, CIRM, Canadian Aviation Regulations, Sickle cell disease, University, Gene, Endocrine & Metabolism Research Institute, Aplastic anemia, Research, Transplant, Immunology, Luca Zaia, Distinguishing, Safety, Cytomegalovirus, HLA, Cancer, Morgan, UCSD, Cell, Acute myeloid leukemia, CAR, CD33, Immune system, Food and Drug Administration, Mortality, LOS, B cell, Radiation, HIV, Clinical trial, Person, Irell & Manella Graduate School of Biological Sciences, Regenerative medicine, AML, City, Beckman Research Institute, Aaron, Haematopoietic system, Food, Vaccine, Pharmaceutical industry, Dentistry, Hope, Leukemia, Hematology
LOS ANGELES, Aug. 9, 2023 /PRNewswire/ -- Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, were awarded $32.3 million from the California Institute for Regenerative Medicine (CIRM) to support three novel Phase 1 clinical trials evaluating innovative cell and gene therapy treatments for patients with HIV, acute myeloid leukemia and severe aplastic anemia.
Key Points:
- Beckman Research Institute of City of Hope was awarded two-thirds of the $50 million in this latest round of CIRM awards, the highest of any entity in the state.
- City of Hope is a leader in gene therapies, including bone marrow and blood stem cells transplants.
- "We are hopeful that this will provide another treatment option for patients with this devastating disease and thankful for CIRM's funding."
- City of Hope has treated patients with sickle cell diseases using this novel therapy in a clinical trial also funded by CIRM.